DNB Asset Management AS Trims Position in Pfizer Inc. $PFE

DNB Asset Management AS trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,266,191 shares of the biopharmaceutical company’s stock after selling 25,566 shares during the period. DNB Asset Management AS’s holdings in Pfizer were worth $32,263,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PFE. West Family Investments Inc. boosted its stake in shares of Pfizer by 24.4% in the third quarter. West Family Investments Inc. now owns 18,637 shares of the biopharmaceutical company’s stock worth $475,000 after acquiring an additional 3,657 shares during the period. Westpac Banking Corp lifted its holdings in Pfizer by 16.3% in the 3rd quarter. Westpac Banking Corp now owns 262,876 shares of the biopharmaceutical company’s stock worth $6,698,000 after purchasing an additional 36,846 shares in the last quarter. Interchange Capital Partners LLC boosted its stake in Pfizer by 43.2% in the 3rd quarter. Interchange Capital Partners LLC now owns 20,206 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 6,095 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Pfizer by 4.2% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 11,396,271 shares of the biopharmaceutical company’s stock valued at $290,377,000 after buying an additional 464,449 shares in the last quarter. Finally, Total Clarity Wealth Management Inc. bought a new stake in shares of Pfizer during the third quarter valued at approximately $878,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $27.61 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market capitalization of $156.97 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47. The firm’s 50-day moving average is $26.13 and its 200 day moving average is $25.41.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 earnings per share. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PFE shares. UBS Group started coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Morgan Stanley cut their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $27.70.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.